Principles for designing an optimal mRNA lipid nanoparticle vaccine
Open accessAbstract
mRNA Lipid nanoparticles (LNPs) have recently been propelled onto the center stage of therapeutic platforms due to the success of the SARS-CoV-2 mRNA LNP vaccines (mRNA-1273 and BNT162b2), with billions of mRNA vaccine doses already shipped worldwide. While mRNA vaccines seem like an overnight success to some, they are in fact a result of decades of scientific research. The advantage of mRNA-LNP vaccines lies in the modularity of the platform and the rapid manufacturing capabilities. However, there is a multitude of choices to be made when designing an optimal mRNA-LNP vaccine regarding efficacy, stability and toxicity. Herein, we provide a brief on what we consider to be the most important aspects to cover when designing mRNA-LNPs from what is currently known and how to optimize them. Lastly, we give our perspective on which of these aspects is most crucial and what we believe are the next steps required to advance the field.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 51 · Cited by 269
Research works printed but not linked: 1
- [42]CDER Product Quality Review (S) NDA 210922 ONPATTRO (Patisiran) Lipid Complex Injection Addendum to Drug Product Quality Review 2017
- Authors
- Kon, E., Elia, U., & Peer, D.
- Affiliations
- Tel Aviv University (IL)
- Israel Institute for Biological Research (IL)
- Corresponding author
- Peer, Dan
- Venue
- Current Opinion in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 73
- Pages
- 329-336
- ISSN
- 0958-1669 (ISSN-L)
- PMC
- PMC8547895
- OpenAlex
- W3208065771
- Cited by
- 269
- References
- 51
- Citations by year
- 2026: 37 · 2025: 65 · 2024: 70 · 2023: 56 · 2022: 38 · 2021: 3
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Current Opinion in Biotechnology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- mRNA lipid nanoparticles, mRNA vaccines, vaccine design, vaccine optimization, vaccine efficacy, vaccine stability, vaccine toxicity, COVID-19 vaccines, mRNA-1273, BNT162b2
- MeSH terms
- COVID-19, mRNA Vaccines, Vaccine Development, BNT162 Vaccine, Humans, Liposomes, Vaccines, Synthetic, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
